Selinexor

DB11942ApprovedInvestigationalSmall moleculeNuclear Export Inhibitors

Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of... This condition is typically treated with high dose bortezomib and dexamethasone chemotherapy followed by an autologous stem-cell transplant.

Chemical structure of Selinexor
Mechanism
Curator reviewed · 5 references
Primary indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Curator reviewed · 5 structured indications
Formula / weight
C17H11F6N7O · 443.313 g/mol (avg)
First approval
Canada, 2022 · United States, 2019 · European Union, 2021
Code names
ATG-010 · KPT-330
Brand names
  • Nexpovio
  • Xpovio 100 Mg Once Weekly Carton

Resolves to

Structure
InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-NSMILESFC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F
Targets
Transporters

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
192Drug interactionsStructured to mechanism, not free text
Sign in
193Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
23Marketed productsAcross 6 countries and 5 labellers
Sign in
1ATC codeIncluding every combination product, plus 8 drug categories
Sign in
18+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Selinexor, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account